Drug Profile
Tarloxotinib - Rain Oncology/University of Auckland
Alternative Names: Hypoxin™; PR 610; Tarlox; Tarloxotinib bromide; TH-4000Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator University of Auckland
- Developer Proacta; Rain Oncology; Threshold Pharmaceuticals
- Class Aniline compounds; Antineoplastics; Imidazoles; Pyridines; Pyridones
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer
- Discontinued Solid tumours; Squamous cell cancer
Most Recent Events
- 31 Dec 2023 Rain Oncology terminates a phase I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) due to business reasons (NCT05313009)
- 14 Mar 2022 University of Auckland plans a phase I trial for Head and neck cancer (Late-stage disease, First-line therapy) in Australia and New Zealand (ACTRN12622000369729)
- 07 Mar 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05313009)